<DOC>
	<DOCNO>NCT02107365</DOCNO>
	<brief_summary>Success rate , retreatment Peg-Interferon/Ribavirin bitherapy , patient infect HCV ( hepatitis C virus ) genotype 4 non-responders first standard treatment , disappoint . The association Asunaprevir Daclatasvir combination standard-of-care bitherapy show increase efficacy treatment non-responders genotype 1-infected patient . Given absence current solution urgent therapeutic need HCV genotype 4-infected patient previously treat pegylated Interferon/Ribavirin , pilot study aim evaluate efficacy safety quadritherapy associate Asunaprevir , Daclatasvir , pegylated Interferon alpha-2a Ribavirin , difficult treat population . 60 subject enrol . The primary endpoint rate sustain virological response ( SVR ) , define undetectable HCV RNA , Week 36 ( 12 week end 24 week quadritherapy ) .</brief_summary>
	<brief_title>Therapy With Asunaprevir , Daclatasvir , Ribavirin Pegylated Interferon Alpha-2a HCV Genotype 4-infected Patients Who Have Failed Previous Therapy With Peg-Interferon/Ribavirin ( ANRS HC32 QUATTRO )</brief_title>
	<detailed_description>The population study present maximum factor non-response retreatment hepatitis C : non-response well follow prior treatment pegylated Interferon Ribavirin , infection HCV genotype 4 , presence cirrhosis ( le 50 % include patient ) could diminish chance SVR standard bitherapy . The likelihood SVR standard bitherapy study population thus consider low , around 15 % . The principal objective multicentric , national , single-arm , open-labeled , non-randomized phase II pilot study 60 patient , assess rate SVR 12 week 24 week quadritherapy determine whether rate significantly great 20 % . The proportion patient present cirrhosis ( define METAVIR F4 score liver biopsy hepatic impulse elastometry ≥ 15 kPa ) limit 50 % patient include .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Adult ≥18 year Infection HCV genotype 4 , confirm detectable HCV RNA ≥ 1000 IU/ml preinclusion Nonresponders prior treatment pegylated Interferon Ribavirin , nonresponse define follow : Nullresponse : reduction le 2 log10 IU/ml HCV viral load D0 treatment week 12 Partial response : reduction least 2 log10 IU/ml HCV viral load D0 treatment week 12 detectable HCV RNA week 12 week 24 without undetectable viral load end treatment AntiHCV treatment discontinue least last 3 month Fibrosis stage , documentation presence absence cirrhosis preinclusion visit : history liver biopsy show cirrhosis lesion ( METAVIR F4 ) , time patient 's history , and/or good quality ( length ≥ 15 mm ≥ 6 portal space ) liver puncture biopsy le 18 month establish METAVIR , and/or hepatic impulse elastometry ( Fibroscan® ) less 6 month good quality ( least 10 measurement incidence IQR le 30 % mean elastometry measure success rate 60 % ) Body weight ≥ 40 kg ≤125 kg Men woman childbearing age heterosexual partner must use two adequate contraception 1 month initiation treatment 7 month end treatment men 4 month treatment woman . Written inform consent ( 2 ) sign patient investigator ( day preinclusion late examination require study ) Patients Health insurance ( Sécurité Sociale Couverture Médicale Universelle ) CHILD B C cirrhosis history decompensated cirrhosis . If Child A cirrhosis , presence varix present hemorrhagic risk ( grade II red spot grade III ) fibroscopy date less 3 year Previous HCV therapy include HCV NS3 protease inhibitor , and/or HCV NS5A replication complex inhibitor and/or HCV NS5B polymerase inhibitor Positive HBs Antigen Confirmed HIV1 HIV2 infection Pregnant breastfeed woman Severe heart lung disease Transplant recipient Uncontrolled dysthyroidism Uncontrolled diabetes Any evolutive ongoing malignant disease , include hepatocellular carcinoma , specifically screen inclusion Consumption alcohol , opinion investigator , obstacle participation patient remain study Drug addiction , investigator 's opinion , obstacle patient 's participation remain study . Patients include programme substitution methadone buprenorphine could include . The opinion consultant addictology recommend patient present current drug use drug use past year . Patients take part another clinical trial 30 day precede inclusion . Patient guardianship , trusteeship judicial protection Hb &lt; 110 g/L Platelets &lt; 80 000/mm3 Polynuclear neutrophil &lt; 1000 /mm3 ( European patient ) &lt; 750 /mm3 ( African patient ) Kidney failure define creatinine clearance &lt; 50mL/mn ( MDRD formula ) Contraindication treatment Ribavirin include history hypersensitivity Ribavirin one excipients Contraindication treatment Daclatasvir Asunaprevir include history hypersensitivity one excipients Contraindication treatment Interferon include psychiatric contraindication . A psychiatrist 's opinion compulsory follow situation : history psychiatric disorder require hospitalisation patient consultation specialist treatment mood stabilizer antipsychotics previous year history psychiatric disorder prior treatment Interferon alpha evidence depression episode , risk suicide , bipolar disorder and/or current behavioral disorder . These patient include psychiatric evaluation specifically authorize use Interferon . History previous HCV treatment premature cessation ( first 6 month ) toxicity . Premature cessation anemia neutropenia authorize absence use erythropoietin polynuclear neutrophil growth factor , respectively . Patients noncompliance history , risk comply study followup timetable Associated treatment likely interfere study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV infection</keyword>
	<keyword>HCV genotype 4</keyword>
	<keyword>Non-responders HCV infect patient</keyword>
	<keyword>Asunaprevir</keyword>
	<keyword>Daclatasvir</keyword>
	<keyword>Pegylated Interferon</keyword>
	<keyword>Ribavirin</keyword>
</DOC>